Highland Capital Management Fund Advisors, L.P. Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Highland Capital Management Fund Advisors, L.P.

$846 Million
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$144.95 - $152.29 $9.43 Million - $9.91 Million	65,091 Added 37.73%	237,616 $35.9 Million
Q2 2022 Aug 15, 2022	BUY	$83.14 - $145.99 $14.3 Million - $25.2 Million	172,525 New	172,525 $25.1 Million
Q4 2020 Feb 16, 2021	SELL	$65.07 - $98.24 $390,419 - $589,440	-6,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$29.01 - $74.23 $58,020 - $148,460	-2,000 Reduced 25.0%	6,000 $439,000
Q1 2020 May 15, 2020	SELL	$27.51 - $57.29 $440,160 - $916,640	-16,000 Reduced 66.67%	8,000 $272,000
Q4 2019 Feb 14, 2020	SELL	$40.86 - $57.65 $143,010 - $201,775	-3,500 Reduced 12.73%	24,000 $1.31 Million
Q3 2019 Nov 14, 2019	BUY	$37.38 - $49.47 $1.03 Million - $1.36 Million	27,500 New	27,500 $1.15 Million

Others Institutions Holding BHVN

# of Institutions

Shares Held

792K

Call Options Held

Put Options Held

View Full List

About Biohaven Pharmaceutical Holding Co Ltd.

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $2.8B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

More about BHVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Highland Capital Management Fund Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Highland Capital Management Fund Advisors, L.P. with notifications on news.

Account